Is GHK-Cu Legal? FDA Status Explained

GHK-Cu is not an FDA-approved drug, but that does not mean every use or product containing GHK-Cu is illegal.

Its U.S. regulatory status depends on several things, including:

• what type of product it is,
• how it is marketed,
• what claims are made about it,
• whether it is topical or systemic, and
• whether it is being used in drug compounding.

As of September 2026, the clearest U.S. regulatory picture is:

• GHK-Cu is not an FDA-approved drug.
• Topical products containing GHK-Cu may be marketed as cosmetics when they comply with applicable cosmetic law and are marketed with cosmetic rather than drug claims.
• It is inaccurate to say that FDA has “approved GHK-Cu as a cosmetic ingredient.” FDA generally does not pre-approve cosmetic ingredients, except for certain color additives.
• GHK-Cu for non-injectable routes is currently listed in FDA's 503A Category 1 of bulk drug substances under evaluation for compounding.
• Category 1 does not mean FDA approval.
• The current Category 1 entry specifically excludes injectable routes.
• FDA separately identifies compounded injectable GHK-Cu as presenting potential safety concerns involving immunogenicity, peptide aggregation and peptide-related impurities.

This article summarizes U.S. federal regulatory information as of September 2026. It is not legal advice. State law and professional-practice requirements may add additional restrictions.

Is GHK-Cu Legal in the United States?

There is no accurate one-word answer that applies to every GHK-Cu product.

The more useful question is:

Legal in what form, for what intended use, and under which regulatory framework?

GHK-Cu Use	Current U.S. Regulatory Context
Topical cosmetic	May be marketed as a cosmetic if it complies with applicable cosmetic safety, labeling and claims requirements
FDA-approved drug	No FDA-approved GHK-Cu drug currently exists
Non-injectable compounded drug	GHK-Cu is currently in FDA 503A Category 1 under evaluation, subject to applicable 503A conditions and FDA's interim policy
Injectable compounded GHK-Cu	Excluded from the current non-injectable Category 1 entry; FDA separately identifies potential significant safety concerns
Dietary supplement	503A compounding status does not establish that GHK-Cu is authorized as a dietary-supplement ingredient

Is GHK-Cu FDA Approved?

No. GHK-Cu is not an FDA-approved drug.

This distinction matters because several different phrases are often used interchangeably online:

• FDA approved,
• FDA regulated,
• FDA listed,
• legal to sell, and
• eligible for certain forms of compounding.

They do not mean the same thing.

FDA's current GHK-Cu documents concern its regulatory treatment as a bulk drug substance nominated for compounding. They do not represent approval of a GHK-Cu drug for anti-aging, skincare, hair growth, bodybuilding or another medical use.

FDA has also previously taken enforcement action involving compounded GHK-Cu drug products when statutory compounding requirements were not satisfied.⁵

Why Isn't GHK-Cu FDA Approved?

The fact that GHK-Cu is not FDA approved does not mean FDA has necessarily reviewed a complete drug application and rejected the peptide.

FDA drug approval is a product- and indication-specific process.

For a new drug to become FDA approved, a sponsor generally must submit an application containing evidence addressing areas such as:

• safety,
• effectiveness,
• manufacturing quality,
• dosage and administration, and
• proposed labeling.

¹⁰

There is currently no FDA-approved GHK-Cu drug product.

The 503A bulk-substance evaluation process is separate from the new-drug approval process.

Therefore:

being evaluated for compounding is not the same thing as being evaluated for FDA drug approval.

Will GHK-Cu Ever Be FDA Approved?

That is currently unknown.

FDA intends to have the Pharmacy Compounding Advisory Committee, or PCAC, consider GHK-Cu in connection with potential inclusion on the 503A Bulks List.¹¹

But that proceeding concerns drug compounding.

It is not a New Drug Application and should not be described as an upcoming FDA approval decision for GHK-Cu.

Even if GHK-Cu were eventually added to the final 503A Bulks List, that would still not make GHK-Cu an FDA-approved drug.

Is GHK-Cu FDA Approved for Skincare?

No.

But this requires some explanation because ordinary cosmetics generally do not go through the FDA drug-approval process in the first place.

FDA generally does not approve cosmetic products or individual cosmetic ingredients before they are marketed, with the main exception of certain color additives.¹

Instead, the company marketing a cosmetic is responsible for complying with applicable federal requirements, including safety and labeling obligations.

Therefore it is inaccurate to say:

“GHK-Cu is FDA approved as a cosmetic ingredient.”

A more accurate description is:

A GHK-Cu cosmetic may be legally marketed without GHK-Cu itself having received FDA premarket approval.

What Is Copper Tripeptide-1?

In cosmetic ingredient terminology, GHK-Cu is commonly referred to as Copper Tripeptide-1.

GHK is the tripeptide glycyl-L-histidyl-L-lysine. When it complexes with copper, it forms what is commonly called GHK-Cu.

Copper Tripeptide-1 appears in many cosmetic formulations intended for skin or scalp use.

Its presence on a cosmetic ingredient label does not mean that the product is an FDA-approved drug.

When Does a GHK-Cu Skincare Product Become a Drug?

In the United States, regulatory classification depends partly on intended use.

A product intended simply to:

• beautify the skin,
• condition the skin,
• improve appearance, or
• promote attractiveness

may fit within the cosmetic framework.

But claims that a product:

• treats or prevents disease,
• restores hair growth,
• heals a medical condition,
• regenerates tissue, or
• affects the structure or function of the body

can cause it to meet the legal definition of a drug.²

This means two products containing the same ingredient can fall into different regulatory categories depending on how they are intended and marketed to be used.

Do You Need a Prescription for GHK-Cu?

It depends on the type of product.

GHK-Cu Cosmetic Products

A topical cosmetic containing Copper Tripeptide-1 does not require a prescription simply because it contains GHK-Cu.

Cosmetic serums, creams and similar products can be sold directly to consumers when they comply with applicable cosmetic requirements.

Compounded GHK-Cu Drugs

Drug compounding under section 503A is different.

Section 503A generally applies when a licensed pharmacist or physician compounds a drug for an identified individual patient based on a valid prescription order, subject to certain statutory conditions and limited rules allowing anticipatory compounding based on historical prescription patterns.¹²

This does not mean a prescription automatically makes every GHK-Cu product or route legally permissible.

Most importantly, FDA's current Category 1 entry is:

“GHK-Cu except for injectable routes of administration.”

⁶

The distinction between prescription status and route of administration therefore matters.

Can You Buy GHK-Cu Over the Counter?

Topical GHK-Cu cosmetics can be sold directly to consumers without a prescription.

However, calling them an “over-the-counter GHK-Cu drug” would usually be misleading.

A cosmetic sold without a prescription is not automatically an OTC drug.

Those are separate regulatory categories.

So a bottle of Copper Tripeptide-1 skincare available in a store or online may simply be a cosmetic product sold directly to consumers rather than an FDA-approved OTC medication.

Is Injectable GHK-Cu FDA Approved?

No.

There is no FDA-approved injectable GHK-Cu drug for:

• anti-aging,
• skin rejuvenation,
• hair growth,
• bodybuilding,
• injury recovery, or
• another therapeutic indication.

FDA also currently identifies GHK-Cu for injectable routes of administration among bulk substances that may present significant safety risks when used in compounding.³

FDA specifically cites potential concerns involving:

• immunogenicity,
• peptide aggregation,
• peptide-related impurities, and
• limited human safety information.

³

The fact that injectable GHK-Cu may be advertised by a clinic or peptide vendor should therefore not be interpreted as FDA approval.

What Is FDA 503A Category 1?

FDA's 503A bulk-substance process is one of the most misunderstood parts of GHK-Cu's regulatory status.

Section 503A of the Federal Food, Drug, and Cosmetic Act provides exemptions from certain federal drug requirements for eligible drug compounding when statutory conditions are met.

One issue is which bulk drug substances may be used.

While FDA evaluates nominated substances for possible inclusion on the final 503A Bulks List, it uses an interim categorization system.⁴

Category 1 means that a nominated substance is under evaluation.

FDA generally may exercise enforcement discretion for eligible 503A compounding involving Category 1 substances when the conditions described in FDA guidance and the statute are satisfied.⁴

Category 1 does not mean:

• FDA approved,
• proven safe and effective,
• approved for a medical indication,
• approved for injection, or
• finally included on the 503A Bulks List.

What Is GHK-Cu's Current 503A Status?

According to FDA's document updated May 14, 2026:

“GHK-Cu (except for injectable routes of administration)” is listed in Category 1.⁶

This means non-injectable GHK-Cu remains under evaluation through FDA's 503A bulk-substance process.

The wording is important:

injectable routes are expressly excluded from that Category 1 entry.

Why Did GHK-Cu's FDA Status Change in April and May 2026?

This short regulatory timeline explains why many online articles now contradict one another.

On April 22, 2026, FDA removed “GHK-Cu except for injectable routes of administration” from Category 1 after its nominations were withdrawn.

The injectable nomination was also recorded as withdrawn during that update.⁷

That was not the final status.

FDA later reported that on May 5 a nominator clarified that it intended to withdraw only the injectable route while retaining its nomination for non-injectable GHK-Cu.

FDA therefore restored:

“GHK-Cu (except for injectable routes of administration)”

to Category 1 in the May 14 update.⁶

Articles relying solely on the April 22 document are therefore outdated.

Is GHK-Cu on the Final 503A Bulks List?

No.

Category 1 is an interim evaluation category.

It is not the same thing as final inclusion on the statutory 503A Bulks List.

FDA evaluates nominated substances and can consult the Pharmacy Compounding Advisory Committee before going through the regulatory process required to add substances to the final list.⁴

FDA currently plans for PCAC to consider GHK-Cu in connection with potential 503A Bulks List inclusion.¹¹

That future review could affect GHK-Cu's compounding status.

It should not be confused with FDA drug approval.

Does Category 1 Mean GHK-Cu Is Legal to Compound?

Category 1 is not blanket permission for any business or individual to manufacture and sell GHK-Cu drugs.

FDA's interim policy concerns eligible compounding conducted within the section 503A framework and subject to its requirements.⁴

Among other things, section 503A addresses issues such as:

• who performs the compounding,
• patient-specific prescriptions,
• which bulk substances are used,
• applicable compounding standards, and
• other statutory conditions.

Category 1 should therefore not be interpreted as:

• general permission for consumer manufacturing,
• authorization for every peptide website,
• authorization for injection, or
• FDA endorsement of safety or effectiveness.

Is Oral GHK-Cu FDA Approved?

No FDA-approved oral GHK-Cu drug exists.

The fact that non-injectable GHK-Cu currently appears in Category 1 does not automatically establish that an oral product is an authorized dietary supplement.

Compounded-drug regulation and dietary-supplement regulation are different legal frameworks.

Consumers should therefore not assume that every oral GHK-Cu product sold online has the same regulatory status.

Can You Legally Buy GHK-Cu Online?

The answer depends on what the website is selling.

Topical Cosmetic Products

A topical GHK-Cu or Copper Tripeptide-1 skincare product may be sold directly to consumers when it is lawfully marketed as a cosmetic and complies with applicable requirements.

Compounded Drug Products

A compounded drug operates under an entirely different regulatory framework.

Section 503A generally involves patient-specific prescription compounding by eligible pharmacists or physicians when statutory conditions are satisfied.¹²

Injectable or “Research” Peptides

The fact that a product is available from an online peptide vendor does not demonstrate that it:

• is FDA approved,
• qualifies under section 503A,
• was manufactured under appropriate standards,
• is legally marketed for human use, or
• has been established as safe.

Likewise, the phrase:

“for research use only”

is not by itself a universal exemption from drug laws.

FDA can consider a product's intended use and the totality of its marketing and distribution.

Is GHK-Cu Legal to Inject?

This question cannot be answered accurately with the blanket statement “yes, injections are legal” or “all GHK-Cu injections are illegal.”

What can be stated clearly is:

• there is no FDA-approved injectable GHK-Cu drug,
• the current GHK-Cu Category 1 entry explicitly excludes injectable routes, and
• FDA has identified potential significant safety concerns with compounded injectable GHK-Cu.

³⁶

Whether a particular medical or compounding activity complies with law can additionally depend on the specific circumstances and applicable federal and state rules.

Is GHK-Cu Legal for Microneedling?

Microneedling should not automatically be treated as ordinary cosmetic application to intact skin.

The regulatory and safety analysis can depend on factors such as:

• the microneedling device,
• needle depth,
• the product used with the procedure,
• the intended route of delivery,
• the claims being made, and
• state professional-practice requirements.

It is therefore too broad to state that all GHK-Cu microneedling is an “FDA-approved use.”

Is GHK-Cu a Research Chemical?

GHK-Cu is a biological copper peptide with decades of scientific research behind it.

But the phrase “research chemical” is not itself a formal FDA approval category.

Online vendors sometimes use the term to describe peptides not marketed as conventional consumer drugs.

Regulatory status still depends on issues such as:

• intended use,
• claims,
• route of administration,
• product category, and
• how the product is manufactured and distributed.

Does Legal Mean GHK-Cu Is Safe?

No.

Legal status, FDA approval and clinical safety are different questions.

A cosmetic can potentially be lawfully marketed without being FDA-approved because ordinary cosmetics generally do not undergo FDA premarket approval.¹

That does not remove the manufacturer's responsibility for product safety and proper labeling.

Likewise, a substance being considered within the 503A compounding framework does not mean FDA has established that it is safe and effective.

This distinction is particularly important with injectable GHK-Cu.

FDA currently notes concerns involving:

• potential immunogenicity,
• peptide aggregation,
• peptide-related impurities, and
• limited human safety information.

³

For a detailed review of adverse effects, contraindications and safety questions, see our GHK-Cu Side Effects guide.

Is GHK-Cu Banned by WADA?

GHK-Cu is not specifically named as an example in the 2026 World Anti-Doping Agency Prohibited List.

However, that does not automatically establish that every systemic use is permitted in tested sport.

WADA's S0: Non-Approved Substances category broadly covers pharmacological substances that:

• are not addressed elsewhere in the Prohibited List, and
• have no current approval by a governmental regulatory health authority for human therapeutic use.

⁸

Because GHK-Cu has no FDA-approved therapeutic drug use, systemic GHK-Cu can raise questions under this broad S0 framework.

That is not the same as saying WADA has specifically listed GHK-Cu by name under S0.

Athletes subject to anti-doping rules should verify the status of the specific substance, product and intended route with their anti-doping organization rather than assuming that “not named” means permitted.

Is Topical GHK-Cu Different for Athletes?

A topical cosmetic product is a different exposure and regulatory context from systemic peptide administration.

However, athletes subject to anti-doping rules are responsible for the substances and products they use.

When eligibility is important, an athlete should verify the specific product and intended use through the appropriate anti-doping authority rather than relying solely on a cosmetic product label.

Why “FDA Regulated” Does Not Mean “FDA Approved”

This is perhaps the most important regulatory concept in the entire GHK-Cu discussion.

A product can fall within FDA's regulatory authority without undergoing FDA premarket approval.

Cosmetics are a clear example.

FDA regulates cosmetics, but ordinary cosmetics and cosmetic ingredients do not require FDA premarket approval, apart from certain color additives.¹

Likewise, the fact that FDA has:

• listed GHK-Cu in a compounding document,
• assigned it Category 1 status,
• created a substance identifier, or
• discussed it in an FDA document

does not mean FDA has approved GHK-Cu as a drug.

Does an FDA Ingredient Listing Mean Approval?

No.

Government substance databases contain records and identifiers used for regulatory and scientific data management.

FDA specifically notes that the existence of a Unique Ingredient Identifier, or UNII, does not imply regulatory review or approval.⁹

A database entry should therefore never be used as proof that GHK-Cu has received FDA drug approval.

Is GHK-Cu Legal Outside the United States?

Regulation is jurisdiction-specific.

Other countries may regulate GHK-Cu differently depending on whether it is marketed as:

• a cosmetic,
• a medicine,
• a compounded preparation,
• a food or supplement product, or
• a research material.

The FDA framework described in this article applies to the United States and should not automatically be applied to Canada, the European Union, the United Kingdom, Australia or other jurisdictions.

GHK-Cu Legal Status: The Bottom Line

• GHK-Cu is not an FDA-approved drug.
• It is inaccurate to describe GHK-Cu as “FDA approved as a cosmetic ingredient.”
• Topical Copper Tripeptide-1 cosmetics can potentially be sold directly to consumers without a prescription when they comply with applicable cosmetic requirements.
• A cosmetic being sold without a prescription does not make it an FDA-approved OTC drug.
• Product claims matter. A cosmetic marketed to treat disease or affect the structure or function of the body may be regulated as a drug.
• Non-injectable GHK-Cu is currently in FDA 503A Category 1.
• Category 1 means under evaluation and subject to an interim policy; it does not mean FDA approval.
• The current Category 1 entry explicitly excludes injectable routes.
• 503A compounding generally involves an identified individual patient and a valid prescription, subject to applicable statutory conditions.
• FDA currently identifies potential safety concerns with compounded injectable GHK-Cu.
• The upcoming PCAC process concerns possible inclusion on the 503A Bulks List, not approval of GHK-Cu as a new drug.
• Legal availability does not establish clinical safety or effectiveness.
• GHK-Cu is not specifically named in WADA's 2026 list, but tested athletes should not assume systemic use is permitted simply because the peptide is not named individually.

Frequently Asked Questions

Is GHK-Cu legal?

There is no single legal status covering every form of GHK-Cu. Cosmetic, compounded-drug and injectable uses fall under different regulatory frameworks.

Is GHK-Cu legal in the USA?

Topical GHK-Cu cosmetics may be lawfully marketed when they meet applicable cosmetic requirements. GHK-Cu is not an FDA-approved drug, and injectable and compounded forms involve different federal and potentially state requirements.

Is GHK-Cu FDA approved?

No. There is currently no FDA-approved GHK-Cu drug.

Why is GHK-Cu not FDA approved?

FDA approval requires approval of a particular drug product and indication through the appropriate application process. GHK-Cu's current 503A compounding evaluation is separate from the FDA new-drug approval process.

Will GHK-Cu become FDA approved?

It is unknown. FDA plans to have PCAC consider GHK-Cu in relation to the 503A Bulks List, but that is a compounding proceeding rather than an application to approve a GHK-Cu drug.

Is GHK-Cu FDA approved for skincare?

No. Ordinary cosmetics and cosmetic ingredients generally do not receive FDA premarket approval. A compliant GHK-Cu cosmetic may be marketed without GHK-Cu itself being “FDA approved.”

Is Copper Tripeptide-1 FDA approved?

It is misleading to describe Copper Tripeptide-1 as an FDA-approved cosmetic ingredient. Ordinary cosmetic ingredients generally do not undergo FDA premarket approval.

Do you need a prescription for GHK-Cu?

Not for an ordinary GHK-Cu cosmetic. Compounded GHK-Cu drugs are different: section 503A generally involves patient-specific prescription compounding when the statutory requirements are met.

Can you buy GHK-Cu over the counter?

Topical GHK-Cu cosmetics can be sold directly to consumers without a prescription. That does not make them FDA-approved OTC drugs.

Is injectable GHK-Cu FDA approved?

No. There is no FDA-approved injectable GHK-Cu drug, and FDA separately identifies potential significant safety concerns with compounded injectable GHK-Cu.

Is GHK-Cu Category 1?

Yes, with an important qualifier. FDA currently lists GHK-Cu except for injectable routes of administration in 503A Category 1. Category 1 means under evaluation, not FDA approved.

Was GHK-Cu removed from Category 1?

Temporarily. FDA removed non-injectable GHK-Cu in April 2026 after nominations were withdrawn, then restored non-injectable GHK-Cu to Category 1 in May after a nominator clarified that only the injectable nomination was intended to be withdrawn.

Can pharmacies compound GHK-Cu?

Non-injectable GHK-Cu currently falls within FDA's Category 1 interim framework when applicable section 503A requirements are met. This is not blanket authorization for every pharmacy, product, route or use.

Can you legally buy GHK-Cu online?

It depends on the product and how it is marketed. A cosmetic, compounded prescription product and injectable research peptide do not share the same regulatory status. Online availability itself proves neither FDA approval nor legal compliance.

Is GHK-Cu legal to inject?

There is no FDA-approved injectable GHK-Cu drug, the current Category 1 entry excludes injections, and FDA identifies potential safety concerns with compounded injectable GHK-Cu. The legality of a particular medical or compounding situation can additionally depend on federal and state requirements.

Does legal mean GHK-Cu is safe?

No. Legal marketing status, FDA approval and clinical safety are separate questions. Human systemic safety data for GHK-Cu remain limited, particularly for injectable use.

Is GHK-Cu banned by WADA?

GHK-Cu is not specifically named on the 2026 WADA Prohibited List. However, WADA's broad S0 category covers certain pharmacological substances without governmental approval for human therapeutic use, so tested athletes should verify their specific intended use with the appropriate anti-doping authority.

References

1. U.S. Food and Drug Administration. FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated . Accessed September 2026.
2. U.S. Food and Drug Administration. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) . Accessed September 2026.
3. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks . GHK-Cu for injectable routes of administration. Accessed September 2026.
4. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act . Accessed September 2026.
5. U.S. Food and Drug Administration. Tailor Made Compounding LLC Warning Letter . April 1, 2020.
6. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A . Updated May 14, 2026.
7. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A . April and May 2026 revision history.
8. World Anti-Doping Agency. 2026 Prohibited List . Section S0: Non-Approved Substances.
9. U.S. Food and Drug Administration Global Substance Registration System. GHK/Copper Substance Record . UNII availability does not imply regulatory review or approval.
10. U.S. Food and Drug Administration. Development & Approval Process for Drugs . Accessed September 2026.
11. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting . GHK-Cu listed for future consideration in connection with the 503A Bulks List.
12. U.S. Food and Drug Administration. Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act . FDA Guidance for Industry.